Cytokines and signal transduction

Best Practice and Research: Clinical Haematology

Volumn 18, Issue 4 SPEC. ISS., 2005, Pages 509-524

  Hideshima, Teru ^a   Podar, Klaus ^a   Chauhan, Dharminder ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bone marrow; Cytokine; Multiple myeloma; Signal transduction

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CYTOKINE; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR; GW 654652; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 15; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; SD 208; SOMATOMEDIN C; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN HERPESVIRUS 8; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOCLAST; PARACRINE SIGNALING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR GROWTH; TUMOR PROMOTION; TUMOR VASCULARIZATION; VIRUS CARCINOGENESIS;

EID: 22144476861     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.01.003     Document Type: Review

References (144)

1. M. Kawano T. Hirano T. Matsuda et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas Nature 332 1988 83-85
2. B. Klein X.G. Zhang M. Jourdan et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6 Blood 73 1989 517-526
3. M.A. Frassanito A. Cusmai G. Iodice & F. Dammacco Autocrine interleukin-6 production and highly malignant multiple myeloma: Relation with resistance to drug-induced apoptosis Blood 97 2001 483-489
4. M. Urashima D. Chauhan H. Uchiyama et al. CD40 ligand triggered interleukin-6 secretion in multiple myeloma Blood 85 1995 1903-1912
5. H. Uchiyama B.A. Barut A.F. Mohrbacher et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates IL-6 secretion Blood 82 1993 3712-3720
6. D. Chauhan H. Uchiyama Y. Akbarali et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB Blood 87 1996 1104-1112
7. D. Gupta S.P. Treon Y. Shima et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications Leukemia 15 2001 1561-1950
8. M. Urashima A. Ogata D. Chauhan et al. Transforming growth factor b1: differential effects on multiple myeloma versus normal B cells Blood 87 1996 1928-1938
9. T. Hideshima D. Chauhan R.L. Schlossman et al. Role of TNF-α in the pathophysiology of human multiple myeloma: Therapeutic applications Oncogene 20 2001 4519-4527
10. B. Dankbar T. Padro R. Leo et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma Blood 95 2000 2630-2636
11. V. Costes M. Portier Z.Y. Lu Interleukin-1 in multiple myeloma: Producer cells and their role in the control of IL-6 production Br J Haematol 103 1998 1152-1160
12. T. Hideshima D. Chauhan P. Richardson et al. NF-κB as a therapeutic target in multiple myeloma J Biol Chem 277 2002 16639-16647
13. T. Hideshima M. Akiyama T. Hayashi et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu Blood 101 2003 703-705
14. Hideshima T, Podar K, Chauhan D, et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 2004; 23: 8766-8776.
15. Hayashi T, Hideshima T, Nguyen AN, et al. TGF-β receptor I kinase inhibitor downregulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 2004; 10: 7540-7546.
16. N.N. Iwakoshi A.H. Lee P. Vallabhajosyula et al. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1 Nat Immunol 4 2003 321-329
17. R. Bataille M. Jourdan X.G. Zhang & B. Klein Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias J Clin Invest 84 1989 2008-2011
18. H. Ludwig D.M. Nachbaur E. Fritz et al. Interleukin-6 is a prognostic factor in multiple myeloma Blood 77 1991 2794-2795
19. H. Ishikawa N. Tsuyama S. Abroun et al. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6 Blood 15 2002 2172-2178
20. T. Taga M. Hibi Y. Hirata et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 Cell 58 1989 573-581
21. N. Nishimoto A. Ogata Y. Shima et al. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130 J Exp Med 179 1994 1343-1347
22. T. Matsuda T. Fukada M. Takahashi-Tezuka et al. Activation of Fes tyrosine kinase by gp130, an interleukin-6 family cytokine signal transducer, and their association J Biol Chem 270 1995 11037-11039
23. I. Kurth U. Horsten S. Pflanz et al. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes J Immunol 162 1999 1480-1487
24. A. Ogata D. Chauhan G. Teoh et al. Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade J Immunol 159 1997 2212-2221
25. A. Ogata D. Chauhan M. Urashima et al. Blockade of mitogen-activated protein kinase cascade signaling in interleukin-6 independent multiple myeloma cells Clin Cancer Res 3 1997 1017-1022
26. R. Catlett-Falcone T.H. Landowski M.M. Oshiro et al. Constitutive activation of STAT-3 signaling confers resistance to apoptosis in human U266 myeloma cells Immunity 10 1999 105-115
27. D. Puthier R. Bataille & M. Amiot IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway Eur J Immunol 29 1999 3945-3950
28. M.M. Oshiro T.H. Landowski R. Catlett-Falcone et al. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells Clin Cancer Res 7 2001 4262-4271
29. A. Brunet A. Bonni M.J. Zigmond et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor Cell 1999 857-868
30. L.V. Madrid C.Y. Wang D.C. Guttridge et al. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-κB Mol Cell Biol 20 2000 1626-1638
31. L.V. Madrid M.W. Mayo J.Y. Reuther & A.S. Baldwin Jr Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of the IκB kinase and activation of the mitogen-activated protein kinase p38 J Biol Chem 276 2001 18934-18940
32. D.P. Brazil J. Park & B.A. Hemmings PKB binding proteins. Getting in on the Akt Cell 111 2002 293-303
33. I. Vivanco & C.L. Sawyers The phosphatidylinositol 3-Kinase AKT pathway in human cancer Nat Rev Cancer 2 2002 489-501
34. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655-1657
35. M. Akiyama T. Hideshima T. Hayashi et al. Nuclear factor-κB p65 mediates tumor necrosis factor α-induced nuclear translocation of telomerase reverse transcriptase protein Cancer Res 63 2003 18-21
36. T. Hideshima N. Nakamura D. Chauhan & K.C. Anderson Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma Oncogene 20 2001 5991-6000
37. D. Chauhan S. Kharbanda A. Ogata et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells Blood 89 1997 227-234
38. D. Chauhan P. Pandey A. Ogata et al. Cytochrome-c dependent and independent induction of apoptosis in multiple myeloma cells J Biol Chem 272 1997 29995-299957
39. L.H. Wei M.L. Kuo C.A. Chen et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway Oncogene 20 2001 5799-5809
40. D. Chauhan T. Hideshima P. Pandey et al. RAFTK/PYK2-dependent and independent apoptosis in multiple myeloma cells Oncogene 18 1999 6733-6740
41. P.K. Epling-Burnette J.H. Liu R. Catlett-Falcone et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression J Clin Invest 107 2001 351-362
42. D. Chauhan P.T.H. Pandey S. Treon et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apopotosis in multiple myeloma cells J Biol Chem 275 2000 27845-27850
43. D. Chauhan D. Auclair E.K. Robinson et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays Oncogene 21 2002 1346-1358
44. D. Chauhan G. Li M. Sattler et al. Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells Oncogene 22 2003 6296-6300
45. X.Y. Wen A.K. Stewart R.R. Sooknanan et al. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells Int J Oncol 15 1999 173-178
46. A.M. Reimold N.N. Iwakoshi J. Manis et al. Plasma cell differentiation requires the transcription factor XBP-1 Nature 412 2001 300-307
47. D. Chauhan G. Li D. Auclair et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays Blood 101 2003 3606-3614
48. M. Urashima B.P. Chen S. Chen et al. The development of a model for the homing of multiple myeloma cells to human bone marrow Blood 90 1997 754-765
49. + multiple myeloma cells Cancer Res 64 2004 4629-4636
50. K. Pulkki T.T. Pelliniemi A. Rajamaki S et al. oluble interleukin-6 receptor as a prognostic factor in multiple myeloma Br J Haematol 92 1996 370-374
51. M.C. Kyrstsonis G. Dedoussis C. Baxevanis et al. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma Br J Haematol 92 1996 420-422
52. R. Stasi M. Brunetti A. Parma et al. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma Cancer 82 1998 1860-1866
53. T.T. Pelliniemi K. Irjala K. Mattila et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group Blood 85 1995 765-771
54. M.J. Calasanz J.C. Cigudosa M.D. Odero et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations Genes Chromosomes Cancer 18 1997 84-93
55. G. Tricot T. Spencer J. Sawyer et al. Predicting long-term (≤5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants Br J Haematol 116 2002 211-217
56. E. Cesarman Y. Chang P.S. Moore et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas N Eng J Med 332 1995 1186-1191
57. S.J. Gao L. Kingsley D.R. Hoover et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma N Eng J Med 335 1996 233-241
58. P.S. Moore C. Boshoff R.A. Weiss & Y. Chang Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV Science 274 1996 1739-1744
59. R. Burger F. Neipel B. Fleckenstein et al. Human Herpesvirus Type 8 interleukin-6 homologue is functionally active on human myeloma cells Blood 91 1998 1858-1863
60. T. Hideshima D. Chauhan G. Teoh et al. Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6 Clin Cancer Res 6 2000 1180-1189
61. J. Molden Y. Chang Y. You et al. A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit J Biol Chem 272 1997 19625-19631
62. Meads MB, Medveczky PG. Kaposi's sarcoma-associated herpesvirus encoded viral interleukin-6 is secreted and modified differently than human interleukin-6: Evidence for a unique autocrine signaling mechanism. J Biol Chem 2004; 279: 51793-51803.
63. J.R. Berenson & R.A. Vescio HHV-8 is present in multiple myeloma patients Blood 93 1999 3157-3166
64. K. Tarte Y. Chang & B. Klein Kaposi's sarcoma-associated herpesvirus and multiple myeloma: Lack of criteria for causality Blood 93 1999 3159-3163
65. D. Chauhan A. Bharti N. Raje et al. Detection of Kaposi's sarcoma herpesvirus-8 DNA sequences in multiple myeloma bone marrow stromal cells Blood 93 1999 1482-1486
66. Raje N, Kica G, Chauhan D, et al. Detection of Kaposi's sarcoma associated herpesvirus gene sequences in primary amyloidosis. Amyloid 2000; 7: 126-132.
67. M.B. Rettig H.J. Ma R.A. Vescio et al. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients [see comments] Science 276 1997 1851-1854
68. J.W. Said M.R. Rettig K. Heppner L et al. ocalization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma Blood 90 1997 4278-4282
69. C. Brander N. Raje P.G. O'Connor et al. Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma Blood 100 2002 698-700
70. H. Yu M.R. Spitz J. Mistry et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis J Natl Cancer Inst 91 1999 151-156
71. S.E. Hankinson W.C. Willett G.A. Colditz et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer Lancet 351 1998 1393-1396
72. J.M. Chan M.J. Stampfer E. Giovannucci et al. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study Science 279 1998 563-566
73. J. Ma M.N. Pollak E. Giovannucci et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3 J Natl Cancer Inst 91 1999 620-625
74. H. Yu & T. Rohan Role of the insulin-like growth factor family in cancer development and progression J Natl Cancer Inst 92 2000 1472-1489
75. T. Standal M. Borset S. Lenhoff et al. Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor Blood 100 2002 3925-3929
76. D.F. Jelinek T.E. Witzig & B.K. Arendt A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth J Immunol 159 1997 487-496
77. M. Ogawa T. Nishiura K. Oritani et al. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line Cancer Res 60 2000 4262-4269
78. C.S. Mitsiades N. Mitsiades V. Poulaki et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/ Akt signaling in human multiple myeloma cells: Therapeutic implications Oncogene 21 2002 5673-5683
79. K. Vanderkerken K. Asosingh F. Braet et al. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells Blood 93 1999 235-241
80. N.L. Ge & S. Rudikoff Insulin-like growth factor I is a dual effector of multiple myeloma cell growth Blood 96 2000 2856-2861
81. C.S. Mitsiades N.S. Mitsiades C.J. McMullan et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors Cancer Cell 5 2004 221-230
82. Y.W. Qiang E. Kopantzev & S. Rudikoff Insulinlike growth factor-I signaling in multiple myeloma: Downstream elements, functional correlates, and pathway cross-talk Blood 99 2002 4138-4146
83. Y.T. Tai K. Podar L. Catley et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of β-1 integrin and phosphatidylinositol 3′-kinase/AKT signaling Cancer Res 63 2003 5850-5858
84. F. Xu A. Gardner Y. Tu et al. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors Br J Haematol 97 1997 429-440
85. Y. Tu A. Gardner & A. Lichtenstein The phosphatidylinositol 3-kinase/ AKT kinase pathway in multiple myeloma plasma cells: Roles in cytokine-dependent survival and proliferative responses Cancer Res 60 2000 6763-6770
86. S. Abroun H. Ishikawa N. Tsuyama et al. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I that highly express IL-6 receptor α myeloma cells Blood 103 2004 2291-2298
87. M. Akiyama T. Hideshima T. Hayashi et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line Cancer Res 62 2002 3876-3882
88. K. Podar Y.T. Tai C.E. Cole et al. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells J Biol Chem 278 2003 5794-5801
89. Podar K, Anderson KC. The pathophysiological role of VEGF in hematological malignancies: Therapeutic implications. Blood; in press.
90. K. Podar Y.T. Tai F.E. Davies et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration Blood 98 2001 428-435
91. K. Podar Y.T. Tai B.K. Lin et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with β-1 integrin- and phosphatidylinositol 3-kinase-dependent PKC α activation J Biol Chem 277 2002 7875-7881
92. A. Vacca D. Ribatti M. Presta et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma Blood 93 1999 3064-3073
93. D. Ribatti A. Vacca B. Nico et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma Br J Cancer 79 1999 451-455
94. S.V. Rajkumar T. Leong P.C. Roche et al. Prognostic value of bone marrow angiogenesis in multiple myeloma Clin Cancer Res 6 2000 3111-3116
95. S. Kumar R. Fonseca A. Dispenzieri et al. Bone marrow angiogenesis in multiple myeloma: Effect of therapy Br J Haematol 119 2002 665-671
96. S. Kumar R. Fonseca A. Dispenzieri et al. Prognostic value of angiogenesis in solitary bone plasmacytoma Blood 101 2003 1715-1717
97. S. Singhal J. Mehta R. Desikan et al. Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 1999 1565-1571 [published erratum appears in N Engl J Med Feb 3; 342(5):364]
98. S.V. Rajkumar R. Fonseca T.E. Witzig et al. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma Leukemia 13 1999 469-472
99. Y.T. Tai K. Podar D. Gupta et al. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells Blood 99 2002 1419-1427
100. B. Lin K. Podar D. Gupta et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment Cancer Res 62 2002 5019-5026
101. K. Podar L.P. Catley Y.T. Tai et al. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment Blood 103 2004 3474-3479
102. S. Dias S.V. Shmelkov G. Lam & S. Rafii VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition Blood 99 2002 2532-2540
103. Le Gouill S, Podar K, Amiot M. et al. VEGF induces MCL-1 upregulation and protects multiple myeloma cells against apoptosis. Blood 2004;104: 2886-2892.
104. T. Hayashi T. Hideshima M. Akiyama et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes Blood 102 2003 1435-1442
105. F. Silvestris P. Cafforio N. Calvani & F. Dammacco Impaired osteoblastogenesis in myeloma bone disease: Role of upregulated apoptosis by cytokines and malignant plasma cells Br J Haematol 126 2004 475-486
106. A.S. Baldwin Jr The NF-κB and I κB proteins: New discoveries and insights Annu Rev Immunol 14 1996 649-683
107. A.A. Beg & A.S. Baldwin Jr The IκB proteins: Multifunctional regulators of Rel NF-κB transcription factors Genes Dev 7 1993 2064-2070
108. E. Zandi D.M. Rothwarf M. Delhase et al. The IκB kinase complex (IKK) contains two kinase subunits, IKKa and IKKb, necessary for IκB phosphorylation and NF-κB activation Cell 91 1997 243-252
109. T.S. Finco & A.S. Baldwin Mechanistic aspects of NF-κB regulation: The emerging role of phosphorylation and proteolysis Immunity 3 1995 263-272
110. M. Roff J. Thompson M.S. Rodriguez et al. Role of IκBα ubiquitination in signal-induced activation of NFκB in vivo J Biol Chem 271 1996 7844-7850
111. T.H. Landowski N.E. Olashaw D. Agrawal & W.S. Dalton Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells Oncogene 22 2003 2417-2421
112. T. Hideshima D. Chauhan Y. Shima et al. Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 2000 2943-2950
113. J.F. Wang Z.Y. Liu & J.E. Groopman The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion Blood 92 1998 756-764
114. J.F. Wang I.W. Park & J.E. Groopman Stromal cell-derived factor-1 α stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: Roles of phosphoinositide-3 kinase and protein kinase C Blood 95 2000 2505-2513
115. T. Hideshima D. Chauhan T. Hayashi et al. The biological sequelae of stromal cell-derived factor-1α in multiple myeloma Mol Cancer Ther 1 2002 539-544
116. C. Moller T. Stromberg M. Juremalm et al. Expression and function of chemokine receptors in human multiple myeloma Leukemia 17 2003 203-210
117. Y. Gazitt & C. Akay Mobilization of myeloma cells involves SDF-1/CXCR4 signaling and downregulation of VLA-4 Stem Cells 22 2004 65-73
118. N. Wright T.L. de Lera C. Garcia-Moruja et al. Transforming growth factor-β1 down-regulates expression of chemokine stromal cell-derived factor-1: Functional consequences in cell migration and adhesion Blood 102 2003 1978-1984
119. X.F. Zhang J.F. Wang E. Matczak et al. Janus kinase 2 is involved in stromal cell-derived factor-1α-induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells Blood 97 2001 3342-3348
120. Y.W. Qiang Y. Endo J.S. Rubin & S. Rudikoff Wnt signaling in B-cell neoplasia Oncogene 22 2003 1536-1545
121. P.W. Derksen E. Tjin H.P. Meijer et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells Proc Natl Acad Sci USA 101 2004 6122-6127
122. Niida A, Hiroko T, Kasai M, et al. DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene 2004; 23: 8520-8526.
123. E. Tian F. Zhan R. Walker et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma N Engl J Med 349 2003 2483-2494
124. A. Vacca D. Ribatti L. Roncali et al. Bone marrow angiogenesis and progression in multiple myeloma Br J Haematol 87 1994 503-508
125. T. Otsuki O. Yamada K. Yata et al. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32.3) and FGFR3 translocation Int J Oncol 15 1999 1205-1212
126. G. Bisping R. Leo D. Wenning et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma Blood 101 2003 2775-2783
127. M. Chesi L.A. Brents S.A. Ely et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma Blood 97 2001 729-736
128. T. Hideshima P.L. Bergsagel W.M. Kuehl & K.C. Anderson Advances in biology of multiple myeloma: Clinical applications Blood 104 2004 607-618
129. Hayashi T, Hideshima T, Nguyen AN, et al. TGF-b receptor I kinase inhibitor downregulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 2004; 10: 7540-7546.
130. Z.Y. Lu X.G. Zhang C. Rodriguez et al. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells Blood 85 1995 2521-2527
131. Z.J. Gu V. Costes Z.Y. Lu et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop Blood 88 1996 3972-3986
132. S.J. Choi J.C. Cruz F. Craig et al. Macrophage inflammatory protein 1-α is a potential osteoclast stimulatory factor in multiple myeloma Blood 96 2000 671-675
133. M. Abe K. Hiura J. Wilde et al. Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma Blood 100 2002 2195-2202
134. H. Hjorth-Hansen A. Waage & M. Borset Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells Br J Haematol 106 1999 28-34
135. I. Tinhofer I. Marschitz T. Henn et al. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma Blood 95 2000 610-618
136. A.T. Brenne T. Baade Ro A. Waage et al. Interleukin-21 is a growth and survival factor for human myeloma cells Blood 99 2002 3756-3762
137. D. Chauhan S.M. Kharbanda A. Ogata et al. Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells J Exp Med 182 1995 1801-1806
138. R. Burger F. Bakker A. Guenther et al. Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival Br J Haematol 123 2003 869-878
139. T. Hideshima & K.C. Anderson Molecular mechanisms of novel therapeutic approaches for multiple myeloma Nat Rev Cancer 2 2002 927-937
140. T. Hideshima P. Richardson D. Chauhan et al. The proteasome inhibitor PS-341inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res. 61 2001 3071-3076
141. N. Mitsiades C.S. Mitsiades V. Poulaki et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells Proc Natl Acad Sci USA 99 2002 14374-14379
142. T. Hideshima P.G. Richardson & K.C. Anderson Targeting proteasome inhibition in hematologic malignancies Rev Clin Exp Hematol 7 2003 191-204
143. T. Hideshima C. Mitsiades M. Akiyama et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 Blood 101 2003 1530-1534
144. T. Hideshima D. Chauhan T. Hayashi et al. Proteasome Inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma Oncogene 22 2003 8386-8393